Drugs that contain Febuxostat

1. List of Uloric drug patents

ULORIC's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7361676 TAKEDA PHARMS USA Solid preparation containing single crystal form
Mar, 2024

(11 months from now)

US8372872 TAKEDA PHARMS USA Methods for concomitant treatment of theophylline and febuxostat
Sep, 2031

(8 years from now)

US9107912 TAKEDA PHARMS USA Methods for concomitant treatment of theophylline and febuxostat
Sep, 2031

(8 years from now)

Market Authorisation Date: 13 February, 2009

Treatment: Use of febuxostat for the management of hyperuricemia in patients suffering from gout and, when used with theophylline without the need for dose adjustment of theophylline

Dosage: TABLET;ORAL

How can I launch a generic of ULORIC before it's patent expiration?
More Information on Dosage

ULORIC family patents

6

United States

4

Japan

3

China

2

Canada

2

Spain

2

Australia

2

Korea, Republic of

2

European Union

1

Hong Kong

1

Slovenia

1

Russia

1

Brazil

1

Portugal

1

Denmark

1

Cyprus

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic